Evidence map›Paper›PMID 40113988›Full record

ArticleCommunications medicine2025

The unprecedented Paxlovid journey from milligrams to millions of patient doses during the Covid-19 pandemic.

Weili Yu, Mahesh K Krishnan, Matt Weekly, Ravi M Shanker, Pankaj Doshi, John A Ragan, Robert A Greene, Brett Gampper, Stéphane Caron, Andrew McKillop and 2 more

Abstract read
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Weili YuPfizer Research & Development, Pharmaceutical Sciences, Pfizer Inc, Groton, CT, USA.ORCID http://orcid.org/0009-0006-7017-4278
Mahesh K KrishnanPfizer Research & Development, Pharmaceutical Sciences, Pfizer Inc, Groton, CT, USA. mahesh.krishnan@pfizer.com.ORCID http://orcid.org/0009-0008-9395-233X
Matt WeeklyPfizer Research & Development, Pharmaceutical Sciences, Pfizer Inc, Groton, CT, USA.
Ravi M ShankerPfizer Research & Development, Pharmaceutical Sciences, Pfizer Inc, Groton, CT, USA.
Pankaj DoshiPfizer Research & Development, Pharmaceutical Sciences, Pfizer Inc, Groton, CT, USA.
John A RaganPfizer Research & Development, Pharmaceutical Sciences, Pfizer Inc, Groton, CT, USA.
Robert A GreenePfizer Global Supply, Pfizer Inc, New York, NY, USA.
Brett GampperPfizer Global Supply, Pfizer Inc, New York, NY, USA.
Stéphane CaronPfizer Research & Development, Pharmaceutical Sciences, Pfizer Inc, Groton, CT, USA.
Andrew McKillopPfizer Research & Development, Pharmaceutical Sciences, Pfizer Inc, Groton, CT, USA.
John LudwigPfizer Research & Development, Pfizer Inc, Chesterfield, MO, USA.
Mikael DolstenPfizer Research, Development & Medical, Pfizer Inc, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40113988
PMCPMC11926161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.